SVB Leerink - More M&A Deals = Better Exit Ops?

I've pretty much established that I'd like to do healthcare IB after a stint at a boutique, so just wanted to see what people think of Leerink's exit ops into PE/GE. I know before they were pretty much ECM deals with M&A scattered around. But saw that they did the Dicerna sale to Novo Nordisk, Xeris Biopharma, BioIQ etc. So looks like more M&A deals recently while keeping up the ECM volume. 

Would you be able to exit to MM/UMM HC PE/GE? Believe there are a couple threads on their reputation, but not much on the above. Thanks!

 
Most Helpful

What part of Healthcare do you want to work in?

I'd make a strong argument Jeff HC is best for anyone looking for HC services PE/GE (a lot of LBO experience, HC service companies trying to grow fast).

If you're talking about life sciences exits to VC/HF, yeah - I'd agree SVB Leerink is up there.

HCIT - variable since a lot of PE deal flow are tech PE/GE (Veritas for example does a lot in healthcare IT, seen a MTS Health Partners analyst exit there).

 

Definitely makes sense, thank you! HC Services is probably more in line with what I can do since I'm assuming VC/HF stuff for Life Sciences requires PHDs and MDs? But do you think if I ended up at Leerink and got mainly Biotech/Biopharma M&A deals I could still break into PE/GE? Or would it be impossible.

 

I'd agree with this. Biopharma M&A isn't relevant for traditional PE, you could maybe LBO a spec pharma or generic company but not very common.

Leerink sends a lot of their guys to growth equity/HFs, the ECM work suffices for people in biopharma so long as they get an understanding of the science.

I'll also second that Jefferies has a good services team and exit ops. The services exits at Leerink should be good given they brought over much of Citi and Guggenheims team.

 

Modi qui dolor quidem inventore impedit incidunt. Possimus debitis sunt et omnis quo. Aliquam eaque vel nihil.

Voluptatibus voluptate aperiam incidunt. Sit consequuntur pariatur voluptatem laudantium necessitatibus. Id quidem sapiente aperiam quidem. Laudantium autem dolores quisquam et ipsum. Provident omnis recusandae commodi et itaque et consequatur.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
kanon's picture
kanon
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
numi's picture
numi
98.8
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”